

# Group B *Streptococcus* Biofilm Regulatory Protein A Contributes to Bacterial Physiology and Innate Immune Resistance

Kathryn A. Patras,<sup>1</sup> Jaclyn Derieux,<sup>1</sup> Mahmoud M. Al-Bassam,<sup>1</sup> Nichole Adiletta,<sup>1</sup> Alison Vrbnac,<sup>1</sup> John D. Lapek,<sup>2,3</sup> Karsten Zengler,<sup>1</sup> David J. Gonzalez,<sup>2,3</sup> and Victor Nizet<sup>1,3</sup>

<sup>1</sup>Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, and <sup>2</sup>Department of Pharmacology, School of Medicine, and <sup>3</sup>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California–San Diego, La Jolla

**Background.** *Streptococcus agalactiae* (group B *Streptococcus* [GBS]) asymptotically colonizes approximately 20% of adults; however, GBS causes severe disease in susceptible populations, including newborns, pregnant women, and elderly individuals. In shifting between commensal and pathogenic states, GBS reveals multiple mechanisms of virulence factor control. Here we describe a GBS protein that we named “biofilm regulatory protein A” (BrpA) on the basis of its homology with BrpA from *Streptococcus mutans*.

**Methods.** We coupled phenotypic assays, RNA sequencing, human neutrophil and whole-blood killing assays, and murine infection models to investigate the contribution of BrpA to GBS physiology and virulence.

**Results.** Sequence analysis identified BrpA as a LytR-CpsA-Psr enzyme. Targeted mutagenesis yielded a GBS mutant ( $\Delta brpA$ ) with normal ultrastructural morphology but a 6-fold increase in chain length, a biofilm defect, and decreased acid tolerance. GBS  $\Delta brpA$  stimulated increased neutrophil reactive oxygen species and proved more susceptible to human and murine blood and neutrophil killing. Notably, the wild-type parent outcompeted  $\Delta brpA$  GBS in murine sepsis and vaginal colonization models. RNA sequencing of  $\Delta brpA$  uncovered multiple differences from the wild-type parent, including pathways of cell wall synthesis and cellular metabolism.

**Conclusions.** We propose that BrpA is an important virulence regulator and potential target for design of novel antibacterial therapeutics against GBS.

**Keywords.** Group B *Streptococcus*; *Streptococcus agalactiae*; biofilm; bacterial cell wall; virulence factor; innate immunity; neutrophil; RNA sequencing; gene regulation

Group B *Streptococcus* (GBS; *Streptococcus agalactiae*) is a member of mucosal microbiota of the intestinal and vaginal tracts, with a global prevalence of approximately 18% [1]. GBS is a preeminent agent of invasive neonatal infection, including early onset sepsis and meningitis, often in the first week of life [2]. Universal culture or risk factor–based screening of pregnant women to guide intrapartum antibiotic prophylaxis has reduced the incidence of early onset neonatal infections [2]. Currently, >90% of the GBS burden occurs outside of the perinatal period, and the incidence in adult and elderly populations is increasing [2, 3]. GBS bloodstream infections account for almost half of clinical manifestations [2, 3]. Acquisition of

antibiotic resistance genes is increasing, along with mutations in penicillin-binding proteins [4].

GBS persistence within the host is a prerequisite for invasive disease. GBS capsular polysaccharide (CPS) promotes biofilm formation [5] and bloodstream survival across multiple serotypes [6, 7] and represents a primary antigen for host recognition. High maternal antibody titers are protective against infant transmission [8], providing rationale for the trivalent GBS glycoconjugate vaccine undergoing clinical trials [9].

GBS mechanisms promoting successful colonization, bloodstream dissemination, and antibiotic resistance, as well as the CPS-based vaccine strategy, all converge on the GBS cell wall. Gram-positive cell walls consist of a peptidoglycan-rich layer that serves as a molecular scaffold for anchoring CPS, wall teichoic acids (WTAs), and surface proteins. In GBS, peptidoglycan anchors CPS and the species-defining group B carbohydrate (GBC) [10]. In contrast to related pathogens, WTAs are absent in GBS; rather, GBC serves as a functional homologue [11]. Enzymatic pathways involved in cell wall anchoring of CPS and GBS are not fully known.

Recently, the LytR-CpsA-Psr (LCP) family of proteins have been identified as important mediators of cell wall integrity and maintenance, further contributing to biofilm formation, blood

Received 6 March 2018; editorial decision 29 May 2018; accepted 2 June 2018; published online June 4, 2018.

Presented in part: 20th Lancefield International Symposium on Streptococci and Streptococcal Diseases, 16–20 October 2018, Denarau Island, Fiji; 6th International Conference on Gram-Positive Pathogens, 10 October 2016, Omaha, Nebraska.

Correspondence: V. Nizet, MD, Division of Host-Microbe Systems and Therapeutics, UC–San Diego, 9500 Gilman Dr, MC 0760, La Jolla, CA 92093-0760 (vnizet@ucsd.edu).

The Journal of Infectious Diseases® 2018;XXX:1–12

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/infdis/jiy341

survival, autolysis, and antibiotic resistance [6, 12, 13]. LCP proteins help tether polysaccharides to the cell wall [14–16] and link WTAs to mature peptidoglycan [17]. GBS possesses 3 LCP family proteins, including the previously characterized *cpsA*, a member of the CPS synthesis operon [6].

Recent molecular insights have highlighted LCP proteins as targets for drug discovery to counteract antibiotic resistance [13, 17]. Here, we designate a previously uncharacterized GBS LCP protein as “biofilm regulatory protein A,” encoded by *brpA*, on the basis of its sequence and phenotypic similarities to *Streptococcus mutans* BrpA [18]. We describe a key role for BrpA in GBS cell chain length, biofilm formation, resistance to whole-blood and neutrophil-mediated killing, vaginal colonization, and systemic virulence, while providing a first look at the genome-wide transcriptional consequences of BrpA deficiency.

## METHODS

### Bacterial Strains and Growth Conditions

GBS CNCTC 10/84 serotype V (catalog no. 49447; American Type Culture Collection [ATCC]) and isogenic strains were grown to stationary phase at 37°C in Todd-Hewitt broth (THB; Hardy Diagnostics) supplemented with 50 µg/mL erythromycin when needed. Cultures were diluted in fresh THB and incubated at 37°C until mid-logarithmic phase (defined as an OD<sub>600</sub> of 0.4).

### Construction of the GBS *brpA* Insertional Mutant

Targeted insertional mutagenesis of *brpA* (GenBank accession no. AIX04136.1 and National Center for Biotechnology Information [NCBI] reference sequence WP\_000708159.1) was performed using the vector pPHY304 as described previously [19] and detailed in the [Supplementary Methods](#).

### GBS Chain Length, Growth, and Autolysis

Bright field images were obtained from random fields at 630 times the original magnification on a Zeiss Axio Scope.A1 with AxioCam mRm. Chain length was determined by counting 25 chains per strain per independent experiment, repeated twice. GBS cultures were grown in THB at pH 5.0, 6.0, or 7.0, and the OD<sub>600</sub> was determined every 30 minutes for 5 hours. For autolysis, cultures were resuspended in phosphate-buffered saline (PBS) at an OD<sub>600</sub> of 0.4, incubated at 37°C, with turbidity measured every 30 minutes, and normalized to  $T = 0$ .

### Biofilm Formation and Microscopy

GBS biofilms were assessed as described elsewhere [20], with 1 adaption: assays were performed in a 200-µL volume, using 96-well plates. For fluorescence microscopy, biofilms were stained with 1 µM Syto13 (Molecular Probes) for 15 minutes, and fluorescent images were obtained at 100 times the original magnification on a Zeiss Axio Scope.A1 with AxioCam mRm.

### Epithelial Adherence

Human vaginal epithelial cells (VK2; catalog no. CRL-2616; ATCC) were grown in keratinocyte serum-free medium (Life Technologies), and bladder epithelial cells (HTB-9; catalog no. 5637; ATCC) were grown in Roswell Park Memorial Institute 1640 medium with 10% fetal bovine serum. Cell lines were cultured at 37°C with 5% CO<sub>2</sub>. Adherence assays were conducted as described previously [21] at a multiplicity of infection (MOI; calculated as the GBS to cell ratio) of 10:1.

### Human Whole-Blood and Neutrophil Killing Assays

Under approval from the UC–San Diego institutional review board, under protocol 070278X, venous blood specimens were obtained under informed consent. Hirudin and heparin were used as an anticoagulant for whole blood and neutrophil isolation, respectively. Neutrophils were isolated using PolymorphPrep (Axis-Shield). For the whole-blood killing assay, 90 µL of blood and 10 µL containing  $1 \times 10^6$  colony-forming units (CFU) of GBS were incubated at 37°C with rotation for 30 minutes, and plated on THB agar, and GBS survival was calculated as a percentage of the inoculum. Neutrophil killing and oxidative burst assays were performed with GBS at a MOI of 1:1 as described previously [22].

### Animal Experiments

Animal experiments were approved by the UC–San Diego Institutional Animal Care and Use Committee. Female CD-1 mice aged 3–4 months were purchased from Charles River Laboratories. Blood specimens were collected via cardiac puncture and killing assays conducted as described above. For neutrophil experiments, neutrophil migration was stimulated by injection of 1 mL of 3% thioglycollate intraperitoneally, and 18 hours after injection, peritoneal lavage was performed using PBS with 5 mM ethylenediaminetetraacetic acid. Neutrophils composed 85%–90% of the total cell population, as determined by Giemsa staining; killing assays were conducted as described above. Vaginal colonization studies were conducted as described [23]. Wild-type (WT) and  $\Delta brpA$  bacteria were combined at a 1:1 ratio, and mice were inoculated with 10 µL ( $2 \times 10^7$  CFU total) into the vaginal tract. The vaginal lumen was swabbed daily, and recovered GBS were quantified on ChroMagar StrepB (DRG International) with or without 50 µg/mL erythromycin, to distinguish strains. For sepsis studies, WT and  $\Delta brpA$  bacteria were combined at a 1:1 ratio, and mice were injected with 100 µL ( $2 \times 10^7$  CFU total) intraperitoneally. After 24 hours, blood specimens were collected via cardiac puncture, and kidneys and spleens were homogenized by adding PBS and silica beads (diameter, 1 mm; Biospec) and shaking at 6000 rpm for 60 seconds, using a MagNA Lyser (Roche). Blood and tissue homogenates were plated on agar with or without 50 µg/mL erythromycin, to distinguish strains.

### RNA Sequencing and Bioinformatic Analysis

GBS strains were grown to an OD<sub>600</sub> of 0.8 in THB at 37°C and subjected to RNA sequencing. Transcriptional analysis of WT and  $\Delta brpA$  strains is detailed in the [Supplementary Methods](#).

### Data Availability

The RNA sequencing data set is deposited at the NCBI Sequence Read Archive (accession no. SRP140532). Other data sets and materials generated and analyzed during this study are available from the corresponding author on request.

### Statistical Analyses

All data were collected from at least 3 biological replicates performed in at least technical duplicate as detailed in [Supplementary Methods](#). Statistical analyses were performed using GraphPad Prism, version 7.03. *P* values of <.05 were considered statistically significant.

## RESULTS

### GBS BrpA Is a Member of the Conserved LCP Family of Proteins

Mass spectrometry of GBS CNCTC 10/84 surface and secreted proteins identified multiple peptide sequences produced by the gene locus W903\_0426. CNCTC 10/84 (Gene Expression Omnibus accession no. CP006910.1) locus W903\_0426 (GenBank accession no. AIX04136.1; NCBI reference sequence WP\_000708159.1), has a predicted 435–amino acid product, which we designate “biofilm regulatory protein A” (BrpA), encoded by *brpA*. Bioinformatic analysis revealed an LCP domain at residues 81–239 (PF03816) [24]. A transmembrane helix model predicted an N-terminal cytosolic domain (residues 1–6) and 1 transmembrane helix (residues 7–29) and that the remaining portion would be extracellular [25] ([Supplementary Figure 1](#)), in agreement with previous analyzes [26]. Within *S. agalactiae* (taxID: 1311), protein BLAST analysis of WP\_000708159.1 found 35 additional unique sequences (representing 678 genomes) with  $\geq 97\%$  sequence identity. Protein-protein BLAST analysis showed 68% identity to *Streptococcus pyogenes* LytR (NCBI reference sequence WP\_063811833.1). Subsequent alignment with *S. pyogenes* LytR, *Streptococcus dysgalactiae* LytR (NCBI reference sequence WP\_042357980.1), and BrpA in *S. mutans* (WP\_019316206.1) was performed ([Figure 1](#)). The LCP domain (amino acids 81–239) exhibited 75% identity across all 4 species. A previous cluster analysis categorized BrpA into LCP cluster F2 containing LytR/BrpA-like proteins of Firmicutes [26]. The other GBS LCP proteins, previously characterized CpsA (NCBI reference sequence WP\_000064987.1), and a yet uncharacterized LCP protein (NCBI reference sequence WP\_000089333.1) were grouped to cluster F3 and F1 ([Supplementary Figure 1](#)).

### GBS BrpA Deficiency Influences Cellular Chain Length, Pigmentation, and Acid Tolerance

LCP proteins control cell envelope maintenance, chain length, and stress responses [13, 18, 27, 28]. To assess the impact of GBS BrpA, we generated an insertional mutant ( $\Delta brpA$ ), using pHY304 to disrupt *brpA* [19]. Bright-field microscopy revealed a 6-fold increase ( $P < .0001$ ) in the chain length of mid-logarithmic-phase GBS  $\Delta brpA$  ([Figure 2A](#)), with median chain length of 4 cells for the parental WT strain and 26 for the  $\Delta brpA$  strain. Transmission electron microscopy revealed no notable aberrant differences in cell shape, size, division planes, nucleoid structure, or cell-envelope electron density in the  $\Delta brpA$  strain ([Supplementary Figure 2](#)). Separation of GBS  $\Delta brpA$  dividing cells appeared similar to that of the WT strain; cells within chains were attached only by the outermost cell wall components ([Supplementary Figure 2](#)). Cellular morphology changes have been reported in LCP double or triple mutants [12, 13, 15], but deficiency of only 1 LCP protein may not impact cell division or morphology [12]. Complementation of  $\Delta brpA$  by using a full-length *brpA* construct under constitutive expression failed to yield viable colonies. Alternatively, the  $\Delta brpA$  mutant was serially passaged in the absence of Erm and screened for loss of the insertion (henceforth referred to as “revertant strains”).

LCP protein CpsA regulates capsule production in GBS [6], which influences buoyancy in liquid culture. Likewise, in planktonic culture,  $\Delta brpA$  organisms exhibited diminished buoyancy as compared to the WT and revertant strains ([Figure 2B](#)). Remarkably,  $\Delta brpA$  colonies possessed enhanced pigmentation with red/orange granadaene [29], compared with WT and revertant strains ([Figure 2C](#)). Since pigmentation and hemolytic activity have been positively correlated historically [19], we examined hemolytic activity of  $\Delta brpA$ , using live bacteria and hemolytic extracts ([Supplementary Figure 3](#)). Interestingly, there was no difference in hemolysis between the WT and  $\Delta brpA$  strains, with the nonhemolytic  $\Delta cylE$  strain serving as a negative control. It has been proposed that granadaene and  $\beta$ -hemolysin are the same molecule [30]; however, we observed WT hemolytic extracts could be partially inactivated with a variety of proteases, suggesting a proteinaceous nature of  $\beta$ -hemolysin ([Supplementary Figure 3](#)). Although rare, hyperpigmented GBS strains that are not also hyperhemolytic have been reported [31].

LCP proteins influence tolerance to environmental and antimicrobial stressors [28, 32]. Although GBS  $\Delta brpA$  exhibited no growth defect at neutral pH level of 7.0, at acidic pH levels of 6.0 or 5.0 it demonstrated significantly impaired growth as compared to WT and revertant strains ([Figure 2D](#)). In contrast, WT and  $\Delta brpA$  strains had equivalent susceptibility to  $\beta$ -lactams antibiotics, chloramphenicol, LL-37, lysozyme, and hydrogen peroxide in minimum inhibitory concentration assays ([Supplementary Table 1](#)). In *S. mutans*, *Psr* deficiency likewise



S. agalactiae	1	<b>MKIWKKITLIMFSATILITTVIALGVYVASAYNFSTNELSKTFKDFKLAKSKSHAIETKPFSS</b>
S. pyogenes	1	<b>MKIGKKIIVIMFTATVLTIVIALGVYVLSAYTFSTIGELSKTFKDFSTSSKSDAIKQTRAFS</b>
S. dysgalactiae	1	<b>MKIGKKIIVMIMATVLTIVIALGVYVLSAYTFSTIGELSKTFKDFSTSSKSDAIKQTKSFS</b>
S. mutans	1	<b>MKIGKKILLIMVAIFLITSLVALGVYATSIYNFSLGEFSKTFKDYGTGSGK.DVIADKPFSS</b>
S. agalactiae	62	<b>ILLMGVDTGSEHRKSKWSGNSDSMILVINEPKTKTKTMTSLERDVLIKLSGPKNNGQTGVE</b>
S. pyogenes	62	<b>ILLMGVDTGSSERASKWEGNSDSMILVTVNEPKTKTKTMTSLERDILITLISGPKNNEMNGVE</b>
S. dysgalactiae	62	<b>ILLMGVDTGSSERTSQWEGNSDSMILVTVNEPKTKTKTMTSLERDILITLISGPKNNDMNGTE</b>
S. mutans	61	<b>ILLMGVDTGSSERTSKWEGNSDSMILVTVNEPKTKTKTMTSLERDILVKLISGSKINDQTYD</b>
S. agalactiae	123	<b>AKINAAYAAGGAEAMIMTVQDLLDINVDYFMQINMQGLVDLVNAVGGITVINKFDFFPISIA</b>
S. pyogenes	123	<b>AKINAAYAAGGACMAIMTVQDLLNITIDNYVQINMQGLIDLVAVGGITVINNEFDFFPISIA</b>
S. dysgalactiae	123	<b>AKINAAYAAGGACMAIMTVQDLLNITIDNYVQINMQGLIDLVAVGGITVINNEFDFFPISIA</b>
S. mutans	122	<b>AKINAAYAAGGAKMAIMTVQDMLDIDKIDKYVQINMEGLVQLVDAVGGITVINHEFDFFPISIE</b>
S. agalactiae	184	<b>ANEPEYKAVVEPGTHKINGEQALVYSRMRYDDPEGDYGRQKQREVIQKVLKILALNSIS</b>
S. pyogenes	184	<b>ENEPEYQATVAPGTHKINGEQALVYARMRYDDPEGDYGRQKQREVIQKVLKILALDSIS</b>
S. dysgalactiae	184	<b>DNEPEYQATVAPGTHKINGEQALVYARMRYDDPEGDYGRQKQREVIQKVLKILALDSIS</b>
S. mutans	183	<b>EHEPEPTASVEPGTHKINGEQALVYSRMRYDDPDG DYGRQKQREVI SKVLKILALDSVS</b>
S. agalactiae	245	<b>SYRKILSAVSNMQINIEISSKTIENLLAYKDSLEHKSQYQKGEDATLSDGGSYQI LTKK</b>
S. pyogenes	245	<b>SYRKILSAVSNMQINIEISSRTIPEILLGFRDALRTIKTYQKGEDATLSDGGSYQIVTS N</b>
S. dysgalactiae	245	<b>SYRKILSAVSNMQINIEISSNTIPEILLGFRDALRTIKTYQKGEDATLSDGGSYQIVTS D</b>
S. mutans	244	<b>KYRKILSAVSNMQINIEISSSTIPEILLGFRDALRTIKTYQKGEDATLSDGGSYQIVTSK</b>
S. agalactiae	306	<b>HLLAVQNRIRKELDKKR..SKTLKTSAILLYEDYGTASNDSSYSSSTQENNYNTIPYSEA</b>
S. pyogenes	306	<b>HLLLEIQNRIRTELGLK..VSQKLTNAIVYENLYGSKSQ.....TVNNYDSS..GQA</b>
S. dysgalactiae	306	<b>HLLLEIQNRIRGELGLK..VTQKLTSAIVYENLYGSSKQ.....SSDINSYDFS..GQS</b>
S. mutans	304	<b>ELLKAQNRIRKQGLGLKSTAEINLKTASLYENFYGGDTS.....TYDSS..SSA</b>
S. agalactiae	365	<b>PPSYSGNTIYSSEINQITTHQSYNNSSTPANNYSNTINTGQADSSGVSNNHGAATPNENT G</b>
S. pyogenes	356	<b>PSYSDSHSYANYSSGVDTGSSYQSASTDQESTAS SHT.PTPSSSSDALAADE SSSSGSG</b>
S. dysgalactiae	356	<b>PSYSDSNS.YSSYSGGSETSPAYQGN TSAQDTITTS SSV.PVVPAPQAEAPVSDSTSDG G</b>
S. mutans	351	<b>SDYSSSGN.YSGSSDYGSSSYGNSSSGSSSDYSGQ.NSYNQGNYPQPAAG...TGIG</b>
S. agalactiae	426	<b>TQPVPGQINP</b>
S. pyogenes	416	<b>SLVPPANINPQT</b>
S. dysgalactiae	414	<b>SDGTTTSLP</b>
S. mutans	406	<b>N</b>

**Figure 1.** Group B *Streptococcus* (GBS) biofilm regulatory protein A (BrpA) alignment with other *Streptococcus* species. *Streptococcus agalactiae* CNCTC 10/84 (Gene Expression Omnibus accession no. CP006910.1) biofilm regulatory protein A (GenBank accession no. A1X04136; National Center for Biotechnology Information [NCBI] reference sequence WP\_000708159.1) aligned with *Streptococcus pyogenes* LytR family transcriptional regulator (NCBI reference sequence WP\_063811833.1), *Streptococcus dysgalactiae* LytR family transcriptional regulator (NCBI reference sequence WP\_042357980.1), and BrpA in *Streptococcus mutans* (NCBI reference sequence WP\_019316206.1) was performed using the Alignment-annotator web server. Amino acid residues with >74% identity are indicated in bold.


does not impact susceptibility to antimicrobials or oxidative stress [12], indicating that LCP proteins differentially influence susceptibility to stressors.

#### BrpA Supports Cell Survival, Biofilm Formation, and Epithelial Colonization

We observed similar rates of autolysis between WT (33%) and  $\Delta brpA$  (36%) strains in PBS (Figure 3A), but cell viability was significantly affected in planktonic cultures. BrpA deficiency led to a 10-fold reduction in viable CFU by day 4 of culture ( $P = .0055$ ) and a 40-fold reduction ( $P < .0001$ ) by day 5 (Figure 3A), although cultures achieved similar pH (approximately 4.5) at all time points (data not shown).

To assess biofilms, WT and  $\Delta brpA$  strains were grown on tissue culture-treated polystyrene for 24h and adherent biomass determined by crystal violet staining [20]. GBS  $\Delta brpA$  was significantly attenuated for biofilm formation, compared with the WT ( $P = .0005$ ) and revertant ( $P = .0174$ ) strains (Figure 3B). Biomass did not differ between WT and revertant strains ( $P = .1840$ ).

Since modification of cell wall components, including the GBC and WTA, impact retention of crystal violet within the cytoplasm [11], we visualized biofilms, using the nucleic acid stain Syto13. Fluorescent images confirmed crystal violet quantification, with limited binding and sparse colonies formed by the  $\Delta brpA$  strain as compared to the WT strain (Figure 3B). GBS strains were incubated with human vaginal (VK2) or bladder (HTB-9) epithelial cells at a MOI of 10:1 for 30 minutes. In both cell types, the  $\Delta brpA$  strain showed significantly lower adherence, compared with the WT strain ( $P = .0006$  for both VK2 and HTB-9 cells; Figure 3C). To characterize effects of BrpA-deficiency in vivo, we used a vaginal colonization model with WT and  $\Delta brpA$  strains administered in competition. Female CD-1 mice were vaginally inoculated with  $1 \times 10^7$  CFU each of WT and  $\Delta brpA$  strains ( $2 \times 10^7$  CFU total/mouse). The vaginal lumen was swabbed daily to measure GBS persistence over 3 days. On all days tested, WT strain loads were significantly higher than  $\Delta brpA$  strain loads, with median differences of  $5.5 \times 10^5$  CFU ( $P < .0001$ ) on day 1,  $3.6 \times 10^5$  CFU ( $P = .0002$ ) on day 2, and  $4.2 \times 10^4$  CFU ( $P = .0002$ ) on day 3



**Figure 2.** Group B *Streptococcus* (GBS) biofilm regulatory protein A (BrpA) contributes to cellular chain length, buoyancy, pigmentation, and acid tolerance. *A*, Bright-field images of wild-type (left) and  $\Delta brpA$  (center) strains in mid-log-phase growth, taken at 630 $\times$  original magnification. Scale bar = 10  $\mu$ m. Quantification of the chain length is shown at right, with data analyzed via the 2-tailed Mann-Whitney *U* test ( $n = 50$ ). Median values with 95% confidence intervals are displayed. Experiments were performed twice independently, with representative images and combined data shown. *B* and *C*, Visualization of stationary-phase cultures (*B*) or colonies (*C*) grown for 18 hours at 37 $^{\circ}$ C in Todd-Hewitt broth (THB) or on THB agar plates, respectively. *D*, Growth curves of GBS strains in THB at specified pH values. Independent replicates ( $n = 3$ ) are shown, with lines indicating mean values  $\pm$  standard errors of the mean. Data were analyzed using 2-way repeated measures analysis of variance with the Tukey multiple comparisons test. \*\*\*\* $P < .0001$ .


(Figure 3D). Collectively, defects in biofilm formation, epithelial adherence, and vaginal persistence of the  $\Delta brpA$  mutant are evidence that BrpA is an important GBS determinant for successful mucosal colonization.

#### BrpA Deficiency Increases GBS Susceptibility to Human Blood and Neutrophil Killing

To assess BrpA in pathogenesis, ex vivo killing assays were performed in human blood specimens. Within 30 minutes, only a median of 10.9% of  $\Delta brpA$  organisms were recovered, compared with 72.4% of WT organisms ( $P = .0089$ ) and 51.1% of revertant organisms ( $P = .0589$ ; Figure 4A). Likewise, in neutrophil killing assays, only a median of 11.5% of  $\Delta brpA$  organisms were recovered, compared with 76.4% of WT organisms ( $P = .0152$ ) and 78.4% of revertant organisms ( $P = .0140$ ; Figure 4B). Neutrophil reactive oxygen species release was significantly greater upon challenge with the  $\Delta brpA$  strain as compared to the WT strain ( $P = .0421$ ; Figure 4C), likely contributing to more-efficient killing of  $\Delta brpA$  bacteria. Thus, loss of BrpA compromises GBS resistance to blood immune components, particularly the microbicidal activity of neutrophils.

#### GBS $\Delta brpA$ Contributes to GBS Survival In Vivo

LCP proteins influence virulence in invertebrate and vertebrate models [6, 28, 33]. Mouse whole-blood specimens killed  $\Delta brpA$  organisms (median survival, 33.3% of the inoculum) more efficiently than WT organisms (109.3%;  $P = .1687$ ) and revertant organisms (123.3%;  $P = .0327$ ; Figure 5A). Similarly, murine peritoneal-derived leukocytes (85%–90% neutrophils) killed  $\Delta brpA$  organisms (median survival, 30.0% of the inoculum) more effectively than WT organisms (80.5%;  $P = .0012$ ) and revertant organisms (70.1%;  $P = .0273$ ; Figure 5B). To characterize BrpA-deficiency in vivo, we used a systemic infection model with WT and  $\Delta brpA$  bacteria administered in competition. Mice were infected intraperitoneally with  $1 \times 10^7$  CFU each of the WT and  $\Delta brpA$  strains ( $2 \times 10^7$  CFU total/mouse), and 24 hours after infection, blood and tissue specimens were collected. Mice effectively cleared both WT and  $\Delta brpA$  organisms from the blood, with no bacteria detected in 10 of 15 and 14 of 15 mice, respectively (Figure 5C). However, WT bacterial loads were significantly higher than  $\Delta brpA$  bacterial loads in both spleens (median difference, 4941 CFU/g;  $P = .0012$ ) and kidneys (297.4 CFU/g;  $P = .0273$ ; Figure 5C).




**Figure 3.** Group B *Streptococcus* (GBS) biofilm regulatory protein A (BrpA) deficiency influences cell survival, biofilm formation, and epithelial cell adherence but not autolysis. (A) Autolysis (left) in cultures of wild-type (WT) and  $\Delta brpA$  organisms suspended in phosphate-buffered saline was measured spectrophotometrically (at OD<sub>600</sub>), using turbidity normalized to  $T=0$ . Viability (right) of WT and  $\Delta brpA$  strains grown in Todd-Hewitt broth (THB) over time, as determined by plating on THB agar. Data from independent replicates ( $n=3$ ) are shown, with symbols representing mean values and lines indicating standard errors of the mean (SEMs). Data were analyzed using 2-way repeated measures analysis of variance with the Sidak multiple comparisons test. B, Biofilm formation of WT,  $\Delta brpA$ , and revertant strains quantified by crystal violet uptake (left). Independent replicates ( $n=6$ ) are shown, and lines represent mean values  $\pm$  SEMs. Data were analyzed using 1-way ANOVA with the Holm-Sidak multiple comparisons test. Fluorescent images of in vitro biofilms (center and right) stained with Syto 13 (green), taken at 100 $\times$  original magnification. Scale bar = 100  $\mu$ m. Experiments were performed twice independently, with representative images shown. C, Adherence of WT (black symbols) and  $\Delta brpA$  (open circles) strains to vaginal (VK2) and bladder (HTB-9) epithelial cells. Independent replicates ( $n=7$ ) are shown, and lines represent median values  $\pm$  95% confidence intervals. Data were analyzed using the 2-tailed Mann-Whitney  $U$  test. D, In a competition model, CD1 mice were inoculated intravaginally with  $1 \times 10^7$  CFU of WT and  $\Delta brpA$  organisms ( $2 \times 10^7$  CFU total/mouse), and bacterial burdens were quantified daily after infection. Symbols represent biological replicates ( $n=18$ ), and paired values (WT and  $\Delta brpA$  CFU) from each mouse are connected with dashed lines. Data were analyzed using the 2-tailed Wilcoxon matched-pairs signed rank test with Spearman rank-order correlation. \*\*\* $P < .001$ , \*\* $P < .01$ , and \* $P < .05$ . NS, not significant.

### BrpA Deficiency Alters GBS Gene Expression

LCP proteins have been identified as transcriptional attenuators, with substantial changes of >200 genes reported [27, 28, 34]. RNA sequencing revealed 793 genes differentially expressed  $\geq 2$ -fold in the  $\Delta brpA$  strain as compared to the WT strain (383 were

upregulated and 410 were downregulated;  $P < .05$ ; [Supplementary Tables 2 and 3](#)). Maximum changes in gene expression were approximately 50-fold. Genes were categorized into 25 functional groups on the basis of RAST annotations to determine molecular pathways differing between the WT and  $\Delta brpA$  strains ([Figure 6](#)).



**Figure 4.** Biofilm regulatory protein A (BrpA)-deficient group B *Streptococcus* (GBS) is more susceptible to killing by human whole blood and neutrophils. Human whole blood (A) and isolated neutrophil (B) killing of wild-type (WT),  $\Delta brpA$ , and revertant strains, expressed as a percentage of the inoculum. Biological replicates (n = 4–7) are shown, with lines indicating median values  $\pm$  95% confidence intervals. C, Reactive oxygen species production by neutrophils stimulated with WT,  $\Delta brpA$ , or phorbol 12-myristate 13-acetate as a positive control. Biological replicates (n = 3) are shown, with lines indicating mean values. Data were analyzed using the Kruskal-Wallis test with the Dunn multiple comparisons test (A and B) and repeated measures 2-way analysis of variance with the Tukey multiple comparisons test (C). \*\* $P < .01$  and \* $P < .05$ . NS, not significant; RFU, relative fluorescent units.

### Metabolism

The most-pronounced differences between strains were genes involving protein metabolism (45% and 20% of fragments per kilobase of transcript per million mapped reads [FPKM] in  $\Delta brpA$  and WT strains, respectively) and carbohydrate uptake/fermentation (13% and 39% of FPKM, respectively). BrpA-deficient GBS showed a propensity for protein synthesis, with increased expression of ribosomal proteins, transfer RNA ligases, and amino acid transporters. Additionally, RNA metabolism was enhanced in the  $\Delta brpA$  strain (3.5% of FPKM), compared with the WT strain (1.7% of FPKM).

### Transcriptional Regulation

We observed significant changes to 37% of the genome in GBS  $\Delta brpA$ , which was more than reported for other LCP mutants [27, 33]. These marked changes may largely be attributed to changes in global transcriptional regulators. GBS has 21 two-component systems (TCS) critical for controlling virulence, adherence, resistance to host defenses, and bacterial metabolism [35]. CovRS, which regulates approximately 27% of the entire genome [35], was not impacted by BrpA deficiency. However, 7 TCS were downregulated in GBS  $\Delta brpA$ , including LytST, FspSR, NsrRK, and 4 TCS, which remain uncharacterized. One TCS, *ditRS*, was upregulated in  $\Delta brpA$  organisms.

Global regulator *codY* was upregulated in GBS  $\Delta brpA$ . CodY has roles in biofilms, acid tolerance, and the stringent response and production of (p)ppGpp [36]. Increased *codY* expression may in part explain increased pigmentation of the  $\Delta brpA$  strain, as a recent study reported decreased pigmentation in  $\Delta codY$  [7].


### Stress Response

Transcripts for stress responses were twice as abundant in the  $\Delta brpA$  strain (2% of FPKM), compared with the WT strain (1% of FPKM), matching phenotypic data of decreased tolerance for acid stress. GBS homologues (*arcABCD*) of the arginine deiminase system, a well-known streptococcal mechanism of countering acid stress, were >10-fold downregulated in GBS  $\Delta brpA$ .

### Cell Wall Synthesis

Transcriptional expression of cell wall synthesis pathways was moderately expanded in  $\Delta brpA$  organisms (3.9% of FPKM), compares with WT organisms (2.6% of FPKM), which may be compensatory if these components are not appropriately anchored. The GBC, CPS, and peptidoglycan biosynthesis operons were increased in GBS  $\Delta brpA$  by >2-fold. Related cell surface proteins penicillin binding protein 2 (Pbp2) and Pbp2X were upregulated 4-fold and 2-fold, respectively, in the  $\Delta brpA$  strain. Enzymes predicted to synthesize LTA were increased





**Figure 5.** Biofilm regulatory protein A (BrpA)-deficient group B *Streptococcus* (GBS) is more susceptible to killing by murine whole blood and neutrophils and is attenuated in an in vivo sepsis model. Murine whole blood (A) or peritoneal-derived leukocytes (85% neutrophils; B) killing of wild-type (WT),  $\Delta brpA$ , and revertant strains, expressed as a percentage of the inoculum. Biological replicates ( $n = 5-7$ ) are shown, with lines indicating median values  $\pm$  95% confidence intervals. C, In a competition model, CD1 mice were infected intraperitoneally with  $1 \times 10^7$  colony-forming units (CFU) of WT and  $\Delta brpA$  strains ( $2 \times 10^7$  CFU total/mouse), and bacterial burdens were quantified 24 hours after infection. Symbols represent biological replicates ( $n = 15$ ), and paired values (WT and  $\Delta brpA$  CFU) from each mouse are connected with dashed lines. Data were analyzed using the Kruskal-Wallis test with the Dunn multiple comparisons test (A and B) and the 2-tailed Wilcoxon matched-pairs signed rank test with Spearman rank-order correlation (C). \*\* $P < .01$  and \* $P < .05$ . NS, not significant.

2–4-fold in  $\Delta brpA$  organisms, as was the *dlt* operon responsible for D-alanine incorporation into LTA, and *iagA*, which forms the diglycosyldiacylglycerol membrane anchor for LTA [37].

#### Pathogenesis and Host Interactions

Virulence gene expression was expanded in GBS  $\Delta brpA$  (7.0% of FPKM) as compared to WT GBS (4.9% of FPKM). Several adhesins were upregulated in the  $\Delta brpA$  strain, including PilB, Srr1, fibrinogen binding proteins FsbA and FbsB, and the fibronectin-binding protein *sfbA*. Additionally, factors important to complement evasion, C5a peptidase and C3-degrading proteinase, were upregulated. Members of the *cyl* operon, with roles in  $\beta$ -hemolysin and pigment production, were downregulated approximately 4-fold, as was Camp factor, by approximately 3-fold.


## DISCUSSION

GBS remains an important pathogen in vulnerable populations, including neonates and elderly individuals [2]. Current antibiotic prophylaxis and treatment and the success of future vaccine and therapeutic strategies depend on targeting GBS surface physiology. We characterize BrpA, an LCP family protein, and demonstrate roles in cell separation, biofilm formation, colonization, and virulence. LCP expression is growth-phase

dependent and typically highest in the early stationary or mid-log phases of growth [18, 28, 32]; similarly, GBS *brpA* expression is 7-fold higher at the mid-log phase, compared with expression during the stationary phase [38]. GBS *brpA* expression is down-regulated in human blood [39] but is not effected by pH [40] or induction of the stringent response [7]. Furthermore, *brpA* is not regulated by TCS LiaRS [41], RgfAC [42], or CovRS [40]. Prior screens had suggested that *brpA* is not an essential gene [43], and we have confirmed this here by insertional disruption.

We noted several changes in GBS physiology with loss of *brpA* organisms, including sedimentation during growth. Loss of buoyancy can result from either GBC [11] or capsule [6] deficiency or can arise due to self-aggregation from loss of D-alanine residues in LTA [44]. LCP proteins affect capsule expression in *S. pneumonia* [45], *S. aureus* [46], and GBS [6], resulting in self-agglutination and sedimentation [13, 33]. Similar to other LCP mutants, including GBS CpsA [6, 18],  $\Delta brpA$  strain elongated chains led to a 6-fold CFU reduction at an OD identical to that of the WT strain; thus, assays yielding small CFU differences (<10-fold) between WT and  $\Delta brpA$  strains are difficult to interpret. When feasible, we made adjustments for the impact of chain length by expressing CFU data as a percentage of CFU input (Figures 4 and 5).





**Figure 6.** Transcriptome analysis of wild-type (WT) and  $\Delta brpA$  strains reveals multiple changes to bacterial physiology and metabolism. Late-logarithmic group B *Streptococcus* (GBS) cultures were subjected to RNA sequencing. Genes were categorized into RAST functional group and data expressed as the percentage of fragments per kilobase of transcript per million mapped reads (FPKM).

In gram-positive bacteria, longer chains correspond to reduced activity of autolytic enzymes [47], and, accordingly, we found that autolysin/murein hydrolase LrgA was downregulated in the  $\Delta brpA$  strain. Many LCP mutants display accelerated autolysis [12–14, 18, 34], but under our conditions, BrpA deficiency did not alter autolysis, as reported for MsrR deficiency in *S. aureus* [32, 33]. Over days, GBS BrpA deficiency accelerated death in static culture, and upregulation of RecA and ClpXP protease homologues support involvement of apoptosis-like programmed cell death pathways [48]. Aberrant stress responses may contribute, since  $\Delta brpA$  organisms also demonstrated reduced acid tolerance, a common trait of LCP mutants [12, 27].

Loss of BrpA influenced GBS-host interactions in both colonization and disease, including a severe biofilm defect. Several surface constituents, including pilus type 2a [49], antigens I/II [20], and CPS [5], promote biofilms, yet all of these constituents are aberrantly expressed in GBS  $\Delta brpA$ , so identification of precise components responsible for the biofilm deficit is a limitation of this study. BrpA plays a prominent role in GBS survival in human whole blood and GBS resistance to neutrophils, likely through modification of CPS. GBS CPS is vital to survival in

blood [7], and its abundant terminal sialic acids suppress neutrophil function through engagement of inhibitory sialic acid-binding immunoglobulin-like lectins (ie, Siglecs) [35]. In vivo, GBS  $\Delta brpA$  was recovered in significantly lower abundance in host tissues in the presence of WT organisms, implying that bacterial fitness, rather than host immune response, is the main contributor of decreased virulence of BrpA-deficient GBS.

BrpA deficiency resulted in significant transcriptional changes to approximately 48% of the entire genome, with a  $\geq 2$ -fold change in 37%. These changes appear specific to the loss of *brpA* and not to polar effects, as expression of immediately downstream loci were not different from findings for WT organisms (Supplementary Figure 4). Of note, transcript expression of several cellular processes contrasted with phenotypic results, a discordance all too familiar in biology. Specifically, while levels of several adhesin transcripts were increased, GBS  $\Delta brpA$  consistently displayed decreased epithelial adherence (Figure 3). Possible explanations include increased capsular expression in GBS  $\Delta brpA$ , which itself inhibits adherence [50], or improper anchoring of adhesins. Additionally, expression of the *cyl* operon responsible for granadaene [29] was downregulated in  $\Delta brpA$  organisms, yet colony pigmentation was increased

(Figure 2). None of the known *cyl* regulators, including CovRS and RovS, were altered in  $\Delta brpA$  organisms, suggesting there remain undescribed transcriptional or posttranslational regulators of the *cyl* operon. Additionally, the disconnect between phenotypic pigmentation and hemolytic activity of the  $\Delta brpA$  strain (Supp. Figure 3) adds to the complexity of the unique nature of GBS pigmentation and  $\beta$ -hemolysis. Genetic manipulation of *brpA* will serve as a tool for future discoveries.

The magnitude of transcriptional changes during *brpA* deficiency may explain our failure to obtain viable complementation under constitutive expression. Conversely, constitutive expression of *cpsA* is not lethal [6]. LCP proteins play distinct roles in cell wall maintenance but may also compensate for each other [16, 17], and increased expression of *cpsA* (by >2-fold) in  $\Delta brpA$  organisms corroborates this. Deletion of all 3 LCP enzymes in *Staphylococcus aureus* does not appear to influence surface protein anchoring [15], but this cannot yet be ruled out in GBS, since expression of several sortases were increased in GBS  $\Delta brpA$ . Contribution of each GBS LCP protein to proper surface anchoring of GBC and CPS is a topic of future study.

LCP proteins are exclusive to bacteria and universally found in gram-positive organisms [26]. As such, they are appealing targets for antimicrobial therapies. Our observations support that the LCP protein BrpA is one such target, owing to its critical involvement in GBS cell wall modification to promote both successful colonization and blood survival within its human host.

### Supplementary Data

Supplementary materials are available at *The Journal of Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

### Notes

**Acknowledgments.** We thank Michael Florio, for breeding and maintaining the mice, and the UC–San Diego vivarium staff, for their assistance.

K. A. P. and V. N. conceived and designed experiments. K.A.P., J.D., N.A., M.M.A., and A.V. performed experiments. K. A. P., M. M. A., and V. N. analyzed and interpreted results. J. D. L, K. Z., and D. J. G. contributed reagents, materials, analyses, discussions, and manuscript edits. K. A. P. and V. N. drafted the manuscript.

**Financial support.** This work was supported by the National Institutes of Health (grants HL107150 and HD090259 to V. N. and grant AR071731 to KZ) and the University of California Chancellor's Postdoctoral Fellowship Program (fellowship to K. A. P.)

**Potential conflicts of interest.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form

for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

### References

1. Russell NJ, Seale AC, O'Driscoll M, et al.; GBS Maternal Colonization Investigator Group. Maternal colonization with Group B streptococcus and serotype distribution worldwide: systematic review and meta-analyses. *Clin Infect Dis* **2017**; 65:100–11.
2. Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive Group B streptococcal disease in the United States, 1999–2005. *JAMA* **2008**; 299:2056–65.
3. Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive Group B streptococcal disease in nonpregnant adults, 1990–2007. *Clin Infect Dis* **2009**; 49:85–92.
4. Metcalf BJ, Chochua S, Gertz RE, Jr., et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive *Streptococcus agalactiae* recovered in the USA. *Clin Microbiol Infect* **2017**; 23:574 e7–e14.
5. Rosini R, Margarit I. Biofilm formation by *Streptococcus agalactiae*: influence of environmental conditions and implicated virulence factors. *Front Cell Infect Microbiol* **2015**; 5:6.
6. Hanson BR, Runft DL, Streeter C, Kumar A, Carion TW, Neely MN. Functional analysis of the CpsA protein of *Streptococcus agalactiae*. *J Bacteriol* **2012**; 194:1668–78.
7. Hooven TA, Catomeris AJ, Bonakdar M, et al. *Streptococcus agalactiae* stringent response enhances virulence and persistence in human blood. *Infect Immun* **2018**; 86:e00612–17.
8. Le Doare K, Faal A, Jaiteh M, et al. Association between functional antibody against Group B streptococcus and maternal and infant colonization in a Gambian cohort. *Vaccine* **2017**; 35:2970–8.
9. Madhi SA, Koen A, Cutland CL, et al. Antibody kinetics and response to routine vaccinations in infants born to women who received an investigational trivalent Group b streptococcus polysaccharide CRM197-conjugate vaccine during pregnancy. *Clin Infect Dis* **2017**; 65:1897–904.
10. Deng L, Kasper DL, Krick TP, Wessels MR. Characterization of the linkage between the type III capsular polysaccharide and the bacterial cell wall of Group B streptococcus. *J Biol Chem* **2000**; 275:7497–504.
11. Caliot É, Dramsi S, Chapot-Chartier MP, et al. Role of the Group B antigen of *Streptococcus agalactiae*: a peptidoglycan-anchored polysaccharide involved in cell wall biogenesis. *PLoS Pathog* **2012**; 8:e1002756.
12. Bitoun JP, Liao S, McKey BA, et al. *Psr* is involved in regulation of glucan production, and double deficiency of *BrpA* and *Psr* is lethal in *Streptococcus mutans*. *Microbiology* **2013**; 159:493–506.

13. Over B, Heusser R, McCallum N, et al. LytR-CpsA-Psr proteins in *Staphylococcus aureus* display partial functional redundancy and the deletion of all three severely impairs septum placement and cell separation. *FEMS Microbiol Lett* **2011**; 320:142–51.
14. Massidda O, Kariyama R, Daneo-Moore L, Shockman GD. Evidence that the PBP 5 synthesis repressor (psr) of *Enterococcus hirae* is also involved in the regulation of cell wall composition and other cell wall-related properties. *J Bacteriol* **1996**; 178:5272–8.
15. Chan YG, Frankel MB, Dengler V, Schneewind O, Missiakas D. *Staphylococcus aureus* mutants lacking the LytR-CpsA-Psr family of enzymes release cell wall teichoic acids into the extracellular medium. *J Bacteriol* **2013**; 195:4650–9.
16. Chan YG, Kim HK, Schneewind O, Missiakas D. The capsular polysaccharide of *Staphylococcus aureus* is attached to peptidoglycan by the LytR-CpsA-Psr (LCP) family of enzymes. *J Biol Chem* **2014**; 289:15680–90.
17. Schaefer K, Matano LM, Qiao Y, Kahne D, Walker S. In vitro reconstitution demonstrates the cell wall ligase activity of LCP proteins. *Nat Chem Biol* **2017**; 13:396–401.
18. Chatfield CH, Koo H, Quivey RG Jr. The putative autolysin regulator LytR in *Streptococcus mutans* plays a role in cell division and is growth-phase regulated. *Microbiology* **2005**; 151:625–31.
19. Pritzlaff CA, Chang JC, Kuo SP, Tamura GS, Rubens CE, Nizet V. Genetic basis for the beta-haemolytic/cytolytic activity of Group B streptococcus. *Mol Microbiol* **2001**; 39:236–47.
20. Chuzeville S, Dramsi S, Madec JY, Haenni M, Payot S. Antigen I/II encoded by integrative and conjugative elements of *Streptococcus agalactiae* and role in biofilm formation. *Microb Pathog* **2015**; 88:1–9.
21. Patras KA, Wescombe PA, Rösler B, Hale JD, Tagg JR, Doran KS. *Streptococcus salivarius* K12 limits Group B streptococcus vaginal colonization. *Infect Immun* **2015**; 83:3438–44.
22. Patras KA, Coady A, Olson J, et al. Tamm-Horsfall glycoprotein engages human Siglec-9 to modulate neutrophil activation in the urinary tract. *Immunol Cell Biol* **2017**; 95:960–5.
23. Patras KA, Doran KS. A murine model of Group B streptococcus vaginal colonization. *J Vis Exp* **2016** Nov 16; (117). doi: 10.3791/54708.
24. Finn RD, Coghill P, Eberhardt RY, et al. The Pfam protein families database: towards a more sustainable future. *Nucleic Acids Res* **2016**; 44:D279–85.
25. Krogh A, Larsson B, von Heijne G, Sonnhammer EL. Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes. *J Mol Biol* **2001**; 305:567–80.
26. Hübscher J, Lüthy L, Berger-Bächi B, Stutzmann Meier P. Phylogenetic distribution and membrane topology of the LytR-CpsA-Psr protein family. *BMC Genomics* **2008**; 9:617.
27. Wen ZT, Baker HV, Burne RA. Influence of BrpA on critical virulence attributes of *Streptococcus mutans*. *J Bacteriol* **2006**; 188:2983–92.
28. Bitoun JP, Liao S, Yao X, et al. BrpA is involved in regulation of cell envelope stress responses in *Streptococcus mutans*. *Appl Environ Microbiol* **2012**; 78:2914–22.
29. Rosa-Fraile M, Rodríguez-Granger J, Haidour-Benamin A, Cuerva JM, Sampedro A. Granadaene: proposed structure of the Group B streptococcus polyenic pigment. *Appl Environ Microbiol* **2006**; 72:6367–70.
30. Whidbey C, Harrell MI, Burnside K, et al. A hemolytic pigment of Group B streptococcus allows bacterial penetration of human placenta. *J Exp Med* **2013**; 210:1265–81.
31. Lupo A, Ruppen C, Hemphill A, Spellerberg B, Sendi P. Phenotypic and molecular characterization of hyperpigmented Group B Streptococci. *Int J Med Microbiol* **2014**; 304:717–24.
32. Rossi J, Bischoff M, Wada A, Berger-Bächi B. MsrR, a putative cell envelope-associated element involved in *Staphylococcus aureus* sarA attenuation. *Antimicrob Agents Chemother* **2003**; 47:2558–64.
33. Hübscher J, McCallum N, Sifri CD, et al. MsrR contributes to cell surface characteristics and virulence in *Staphylococcus aureus*. *FEMS Microbiol Lett* **2009**; 295:251–60.
34. Lazarevic V, Margot P, Soldo B, Karamata D. Sequencing and analysis of the *Bacillus subtilis* lytRABC divergon: a regulatory unit encompassing the structural genes of the N-acetylmuramoyl-L-alanine amidase and its modifier. *J Gen Microbiol* **1992**; 138:1949–61.
35. Patras KA, Nizet V. Group B streptococcal maternal colonization and neonatal disease: molecular mechanisms and preventative approaches. *Front Pediatr* **2018**; 6:27.
36. Lemos JA, Nascimento MM, Lin VK, Abranches J, Burne RA. Global regulation by (p)ppGpp and CodY in *Streptococcus mutans*. *J Bacteriol* **2008**; 190:5291–9.
37. Doran KS, Engelson EJ, Khosravi A, et al. Blood-brain barrier invasion by Group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. *J Clin Invest* **2005**; 115:2499–507.
38. Sitkiewicz I, Musser JM. Analysis of growth-phase regulated genes in *Streptococcus agalactiae* by global transcript profiling. *BMC Microbiol* **2009**; 9:32.
39. Mereghetti L, Sitkiewicz I, Green NM, Musser JM. Extensive adaptive changes occur in the transcriptome of *Streptococcus agalactiae* (Group B streptococcus) in response to incubation with human blood. *PLoS One* **2008**; 3:e3143.
40. Santi I, Grifantini R, Jiang SM, et al. CsrRS regulates Group B Streptococcus virulence gene expression in response to environmental pH: a new perspective on vaccine development. *J Bacteriol* **2009**; 191:5387–97.
41. Klinzing DC, Ishmael N, Dunning Hotopp JC, et al. The two-component response regulator LiaR regulates cell wall

- stress responses, pili expression and virulence in Group B *Streptococcus*. *Microbiology* **2013**; 159:1521–34.
42. Gendrin C, Lembo A, Whidbey C, et al. The sensor histidine kinase RgfC affects Group B streptococcal virulence factor expression independent of its response regulator RgfA. *Infect Immun* **2015**; 83:1078–88.
  43. Hooven TA, Catomeris AJ, Akabas LH, et al. The essential genome of *Streptococcus agalactiae*. *BMC Genomics* **2016**; 17:406.
  44. Poyart C, Lamy MC, Boumaila C, Fiedler F, Trieu-Cuot P. Regulation of D-alanyl-lipoteichoic acid biosynthesis in *Streptococcus agalactiae* involves a novel two-component regulatory system. *J Bacteriol* **2001**; 183:6324–34.
  45. Eberhardt A, Hoyland CN, Vollmer D, et al. Attachment of capsular polysaccharide to the cell wall in *Streptococcus pneumoniae*. *Microb Drug Resist* **2012**; 18:240–55.
  46. Wang Y, Sun D, Song F, Hu Y, Smith DE, Jiang H. Expression and regulation of the proton-coupled oligopeptide transporter PhT2 by LPS in macrophages and mouse spleen. *Mol Pharm* **2014**; 11:1880–8.
  47. Buist G, Kok J, Leenhouts KJ, Dabrowska M, Venema G, Haandrikman AJ. Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of *Lactococcus lactis*, a muramidase needed for cell separation. *J Bacteriol* **1995**; 177:1554–63.
  48. Bayles KW. Bacterial programmed cell death: making sense of a paradox. *Nat Rev Microbiol* **2014**; 12:63–9.
  49. Rinaudo CD, Rosini R, Galeotti CL, et al. Specific involvement of pilus type 2a in biofilm formation in Group B *Streptococcus*. *PLoS One* **2010**; 5:e9216.
  50. Tamura GS, Nittayajarn A. Group B streptococci and other gram-positive cocci bind to cytokeratin 8. *Infect Immun* **2000**; 68:2129–34.